Processa Pharmaceuticals, Inc. (PCSA)

Market Cap	5.56M -36.1%
Revenue (ttm)	n/a
Net Income	-13.44M
EPS	-5.59
Shares Out	2.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,837
Open	2.080
Previous Close	2.160
Day's Range	1.980 - 2.110
52-Week Range	1.670 - 14.243
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About PCSA

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: PCSA

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 10, 2026

Data Sources Report a data error